Subcutaneous Amivantamab Leads to Unexpected OS Improvement vs. IV Dosing in Refractory, EGFR+ Advanced NSCLC

KRYSTAL-12 Supports Previous Evidence Showing Adagrasib is Superior to Docetaxel in Pretreated Advanced KRAS-mutated NSCLC

Cytisine: A New Opportunity in the UK for the Treatment of Tobacco Dependency

Recently Reported Evidence Leads to Approvals for Alectinib, Osimertinib

Patient Advocate Ivy B. Elkins Leaves Lasting Legacy

Investigators Report Efficacy, Safety Analysis of Tarlatamab in SCLC Patients With or Without Baseline Brain Metastases

Data Look Promising for First-line Sotorasib, Platinum-based Chemotherapy Combination for KRAS-mutant NSCLC

Osimertinib Plus Chemotherapy May Improve CNS Activity in Advanced EGFR-positive NSCLC

Journal of Thoracic Oncology’s Impact Factor Rises Again; JTO Clinical and Research Reports Receives First Impact Factor

Gender Disparity in Lung Cancer

BEAT-meso Trial Again Identifies Non-epithelioid Mesothelioma as Distinct Population

Concurrent IO with Chemoradiotherapy: Insights from PACIFIC-2